| DIRECT COMPETITOR COMPARISON | |
| THRX | AZN | CBST | PFE | Industry | | Market Cap: | 834.57M | 67.25B | 975.23M | 150.01B | 99.24M | | Employees: | 191 | 65,000 | 554 | 81,800 | 65 | | Qtrly Rev Growth (yoy): | -8.10% | 5.50% | 27.70% | -2.90% | 19.70% | | Revenue (ttm): | 26.50M | 32.05B | 526.58M | 45.82B | 14.01M | | Gross Margin (ttm): | -154.41% | 82.24% | 51.53% | 86.61% | 65.67% | | EBITDA (ttm): | -69.40M | 13.52B | 157.04M | 21.31B | -12.30M | | Oper Margins (ttm): | -281.68% | 37.85% | 27.60% | 37.42% | -137.11% | | Net Income (ttm): | -79.02M | 7.22B | 193.33M | 8.09B | N/A | | EPS (ttm): | -1.263 | 4.98 | 2.732 | 1.204 | -0.32 | | P/E (ttm): | N/A | 9.31 | 6.16 | 15.44 | 16.76 | | PEG (5 yr expected): | N/A | N/A | 0.59 | 5.99 | 1.32 | | P/S (ttm): | 32.14 | 2.05 | 1.85 | 3.22 | 9.68 |
|
| AZN = AstraZeneca plc | | CBST = Cubist Pharmaceuticals Inc. | | PFE = Pfizer Inc. | | Industry = Biotechnology | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.08 | 0.49% | 57.77B | 12.45 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.45 | 0.15% | 13.72B | 15.88 | | Genzyme Corp. | GENZ | 51.52 | 2.26% | 13.67B | 29.37 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.98 | 0.04% | 42.28B | 18.17 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.89 | 1.41% | 9.08B | 1038.57 | | Teva Pharmaceutical Industries Limited | TEVA | 53.16 | -0.21% | 46.83B | 48.64 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.81 | 2.05% | 4.01B | 19.49 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 12.08 | 0.00% | 3.00B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.29 | -0.05% | 5.59B | 112.21 | | Pfizer Inc. | PFE | 18.59 | 1.53% | 150.01B | 15.44 | | Johnson & Johnson | JNJ | 63.30 | 0.19% | 174.65B | 13.82 | | GlaxoSmithKline plc | GSK | 42.88 | 1.42% | 108.70B | 13.53 | | Sanofi-Aventis | SNY | 39.46 | 2.15% | 103.03B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.85 | 0.99% | 126.85B | 16.72 | | RHHBY.PK | 42.29 | 2.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 2.50% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.41 | 0.31% | 84.16B | 14.74 | | Bristol-Myers Squibb Co. | BMY | 25.65 | 1.95% | 50.81B | 13.27 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | PFE | | INSIDE WASHINGTON: Stream of WH health care visits
Thu 4:11pm -
AP | | • | PFE | | Pfizer Increases R&D Commitment in China
Thu 3:09am -
at Seeking Alpha | | • | PFE | | AP IMPACT: A stream of WH health care visits
Wed, Nov 25 -
AP | | • | PFE | | Sitting Atop An Earnings Powder Keg
Wed, Nov 25 -
at Forbes.com | | • | PFE | | CORRECTED - US sees rise in secondary infections after flu
Wed, Nov 25 -
at Reuters | | • | PFE | | Prospecting for Stocks: Novartis
Wed, Nov 25 -
at Motley Fool | | • | AZN | | The Group Behind The Mammogram Guidelines
Wed, Nov 25 -
at Forbes.com | | • | AZN | | Novartis opens new flu vaccine plant in US
Tue, Nov 24 -
at Reuters | | • | CBST | | CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Mon, Nov 23 -
EDGAR Online | | • | AZN | | Sage Advice On Vytorin
Mon, Nov 23 -
at Forbes.com | | • | AZN | | CORRECTED - Next-generation flu vaccine plant to open in U.S.
Mon, Nov 23 -
at Reuters | | • | AZN | | Good News for Bristol-Myers
Mon, Nov 23 -
Zacks.com | | • | AZN | | Worse Than You Think
Fri, Nov 20 -
at Forbes.com | | • | CBST | | Biotech Stocks for a Possible Year-End Rally
Wed, Nov 18 -
at Seeking Alpha | | • | CBST | | Options Boil on Biotech Buyout Rumors
Thu, Nov 12 -
at CNBC | | • | CBST | | Counting On Cubist To Gain A Bit More
Thu, Nov 12 -
at Forbes.com | | • | CBST | | The Boston Globe names Cubist to Globe 100's Top Places to Work '09
Mon, Nov 9 -
Business Wire | | • | CBST | | Alnylam slips on Q3 loss, cautious outlook
Thu, Nov 5 -
at bizjournals.com | | | All Headlines for these symbols... |
|
|
|
0.29% Nasdaq 
0.27 (2.01%) 
Competitors
